Ethris mission is to redefine mRNA medicines through best-in-industry delivery, stability,and nebulization technology.
Ethris is developing mRNA-based therapeutics and vaccines to treat patients with (rare) respiratory disorders and infectious diseases.
Its novel, proprietary technology platform consisting of SNIM RNA , SNaP LNP and Stabilizer preventing LNP aggregation which affords multi-route, multi-cargo delivery options for intramuscular, inhaled or nasal administration and suitable for several genetic medicine payloads including mRNA and gene editing technologies such as CRISPR/Cas.
Platform capabilities overcome key obstacles of currently available mRNA and LNP technology through superior stability removing ultra-cold chain requirements, potent delivery through proprietary SNaP LNP, best-in-class nebulization and improved tolerability through SNIM RNA.
Ethris is developing mRNA-based therapeutics and vaccines to treat patients with (rare) respiratory disorders and infectious diseases.
Its novel, proprietary technology platform consisting of SNIM RNA , SNaP LNP and Stabilizer preventing LNP aggregation which affords multi-route, multi-cargo delivery options for intramuscular, inhaled or nasal administration and suitable for several genetic medicine payloads including mRNA and gene editing technologies such as CRISPR/Cas.
Platform capabilities overcome key obstacles of currently available mRNA and LNP technology through superior stability removing ultra-cold chain requirements, potent delivery through proprietary SNaP LNP, best-in-class nebulization and improved tolerability through SNIM RNA.
.png)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Bavaria
Company HQ Country:
Germany
Year Founded:
2009
Main Therapeutic Focus:
Respiratory
Lead Product in Development:
Lead indications in rare respiratory diseases including, primary ciliary dyskinesia (PCD) and pulmonary alveolar proteinosis (PAP), entering the clinic in 2024 and 2025 respectively.
Infectious diseases: Viral prophylaxis and virus induced asthma exacerbations (CTA Q2/2023), and vaccines (i.m. and nasal platform) including a CEPI funded pan beta-coronavirus vaccine.
Development Phase of Primary Product:
NDA Preparation/In Review
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1-3
Speaker
